EF Hutton Initiates Coverage On CalciMedica with Buy Rating, Announces Price Target of $17
Portfolio Pulse from Benzinga Newsdesk
EF Hutton analyst Tony Butler initiates coverage on CalciMedica (NASDAQ:CALC) with a Buy rating and announces a price target of $17.
June 20, 2023 | 11:11 am
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
EF Hutton initiates coverage on CalciMedica with a Buy rating and a price target of $17.
The Buy rating and price target announcement by EF Hutton analyst Tony Butler is a positive signal for CalciMedica's stock. This recommendation suggests that the analyst believes the stock has potential for growth and is undervalued, which could lead to an increase in demand and a short-term positive impact on the stock price.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100